Susanna Buergel

A partner in the Litigation Department, Susanna serves as co-chair of the Securities Litigation and Enforcement Group. Noted by clients as an “exceptional lawyer” who is “absolutely brilliant, knows the law inside-out,” and has a “keen understanding of exactly what [they] need, and a laser focus on delivering it,” Susanna has extensive experience handling a broad range of matters, with particular emphasis defending financial institutions and corporations in complex securities and commercial matters in federal and state courts across the country. She also regularly represents clients before the Securities and Exchange Commission, the Department of Justice and numerous other federal and state regulatory authorities. Susanna has been recognized by numerous publications and directories.

Susanna served as articles editor of the Columbia Law Review and was a Harlan Fiske Stone Scholar. She is an adjunct lecturer in law at Columbia Law School and currently teaches a course in trial practice.

• Citigroup in multiple matters, including its Second Circuit victory allowing corporations to enter into federal regulatory consent judgments without admitting wrongdoing; its victory in Delaware Chancery Court securing the dismissal of a claim that Citigroup aided and abetted alleged breaches of fiduciary duty in its role as a financial advisor to Tesaro; and its victories dismissing False Claims Act litigations alleging municipal bond underwriters defrauded states, among others.
• Nikola Corporation, a manufacturer of heavy-duty commercial battery-electric vehicles, and several of its officers and directors, in the dismissal of a putative securities class action in the District of Arizona, as well as ongoing related derivative litigation in Arizona and Delaware, regarding alleged misstatements about the company’s products and performances.
• Fresenius Kabi AG, a German healthcare company, at a trial in Delaware Chancery Court in which Fresenius successfully terminated its proposed $4.3 billion merger with Akorn Pharmaceuticals Inc., a U.S.-based generic drug manufacturer, on grounds of a “material adverse change” in Akorn’s business after Fresenius learned of Akorn’s alleged violations of U.S. Food and Drug Administration standards on data-integrity requirements.
• Viking Global Investors LP, a successful hedge fund, in a dispute in Delaware Chancery Court.
• Virtu Financial, in litigation arising out of Virtu Financial’s $1.4 billion acquisition of Knight Capital Group, including the successful resolution of a preliminary injunction challenging the transaction under Section 202 of the Delaware Corporation Law.

• Securities
• White collar crime
• Litigation
• Restructuring Litigation
• Internal Investigations
• Cryptocurrency & Blockchain
• Financial Services

• J.D. Columbia Law School, 1999
• B.A. Columbia University, 1996

• New York State Bar